The ELF Test as a Universally Available Prognostic Tool for Enhancing NASH Patient Care
Perspectives from hepatology and endocrinology
The Enhanced Liver Fibrosis (ELF™) Test is the first blood test granted De Novo marketing authorization by FDA for prognosis in advanced fibrosis due to NASH. Watch this program to hear the clinical perspectives from two clinical thought leaders on how they see the ELF Test positively impacting care for NASH patients with advanced liver fibrosis.
H. Roma Levy, MS
Clinical Expert, Liver Disease
Siemens Healthineers
Endocrinologist and Obesity Medicine Specialist
Atlanta Endocrine Associates, Atlanta, GA
Director of Fatty Liver Program
Cedars Sinai, Los Angeles, CA
The products/features mentioned here are not commercially available in all countries. Their future availability cannot be guaranteed.
In the U.S., the ELF Test is indicated as a prognostic marker in conjunction with other laboratory findings and clinical assessments in patients with advanced fibrosis (F3 or F4) due to non-alcoholic steatohepatitis (NASH) to assess the likelihood of progression to cirrhosis and liver-related clinical events.